Resonance energy transfer sensitises and monitors in situ switching of LOV2-based optogenetic actuators by Li, Li-Li et al.
ARTICLE
Resonance energy transfer sensitises and monitors
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Engineered light-dependent switches provide uniquely powerful opportunities to investigate
and control cell regulatory mechanisms. Existing tools offer high spatiotemporal resolution,
reversibility and repeatability. Cellular optogenetics applications remain limited with diffusible
targets as the response of the actuator is difficult to independently validate. Blue light levels
commonly needed for actuation can be cytotoxic, precluding long-term experiments. We
describe a simple approach overcoming these obstacles. Resonance energy transfer can be
used to constitutively or dynamically modulate actuation sensitivity. This simultaneously
offers on-line monitoring of light-dependent switching and precise quantification of
activation-relaxation properties in intact living cells. Applying this approach to different
LOV2-based switches reveals that flanking sequences can lead to relaxation times up to 11-
fold faster than anticipated. In situ–measured parameter values guide the design of target-
inhibiting actuation trains with minimal blue-light exposure, and context-based optimisation
can increase sensitivity and experimental throughput a further 10-fold without loss of tem-
poral precision.
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Optogenetic methods are increasingly important through-out biology, dissecting spatiotemporal properties of sig-nalling networks and addressing fundamental questions
in pathology, physiology and even psychology in intact organ-
isms. Blue-light photoreceptors such as LOV2 are among the
most popular cellular optogenetics photosensors1. However, blue
light can perturb cells, potentially complicating long-term (hours-
days) optogenetic modulation1,2. LOV2 can be indirectly sensi-
tised by tuning relaxation3, but this compromises time-resolution.
Optogenetics has a unique potential to impose or modulate
complex time-encoded inputs on cellular targets, and establish
long-term manipulation and mimicry of periodic and pulsatile
biological phenomena4,5. It would be valuable to increase sensi-
tivity while maintaining time-resolution. A second difficulty
optimising optogenetic regulators for new targets is that real-time
in situ detection of photosensor switching has not been reported.
Except in specific cases where protein translocation or other
visualised downstream phenomena are targeted, it is hard to
know whether an actuator has been switched. Relaxation rate
constants are obtained by cell-free spectroscopy3,6 and occa-
sionally with heavily modified constructs not subsequently used
for experimental actuation7. LOV2 designs that modify Jα, the
moiety regulated by light-dependent switching, can accelerate
cell-free relaxation >30-fold8. Rational design of illumination
paradigms requires in situ relaxation and activation rates.
Without this information, validation and use of optogenetic tools
remain challenging tasks.
Here we present a simple method addressing these needs,
simultaneously increasing light sensitivity of an optogenetic switch
while providing on-line detection of activation and relaxation.
Engineered resonance energy transfer (RET) between a mTur-
quoise2 fluorescent protein and FMN-bound AsLOV2 increases
switch sensitivity. We demonstrate this with an optically-regulated
nuclear export sequence (NES). Similar results are obtained with the
optogenetic JNK inhibitor, optoJNKi. RET also causes mTurquoise2
quenching by dark-state AsLOV2. Blue-light generates the cysteine
adduct that drives the actuator’s conformational change, leading to
dequenching. LOV2 switching is thus directly observed as fluor-
escent tag dequenching. Darkness allows cysteine adduct decay and
recovery of ground-state AsLOV2, regenerating tag quenching.
Dequench-requench dynamics reveals activation and relaxation
rates of AsLOV2 switching in intact living cells. This generalises to
other fluorescent protein tags and AsLOV2-based actuators. Strik-
ingly, LOV2 relaxation in actuators was up to 11-fold faster than
expected from AsLOV2 spectroscopy. The differences in relaxation
time could be explained by the impact of sequences flanking the
LOV2 domain rather than an effect of the in vivo environment.
Selection of fluorescent tags and consideration of activation-
relaxation parameters facilitates minimal photon exposure proto-
cols for JNK pathway regulation. Finally, comparison of LOV2
FRET-derived parameters with target pathway kinetics guides
optogenetic actuator optimisation to further reduce blue light
requirements tenfold and increase experimental throughput tenfold.
This facilitates repeatable and relatively non-invasive interrogation
of bidirectional pathway dynamics that could not be achieved by
pharmacological approaches. We anticipate the methodology
described could promote wider, more efficient application of cel-
lular optogenetics in diverse experimental settings.
Results
Fused fluorescent protein determines actuation sensitivity.
Blue-light activated optogenetic tools are commonly tagged with
red fluorescent proteins6,9, verifying construct expression without
activation. This occupies blue and yellow-green excitation chan-
nels, and multiplexing with fluorescent probes becomes difficult.
A cyan tag allows recording of actuator expression without
occupying other channels, permitting multiplexing with yellow to
infra-red channels. However, there might be unintended con-
sequences—spectral overlap with proximal (within 5 nm) pho-
tosensor chromophores (flavins in LOV2 and cryptochromes)
may permit RET, influencing actuator sensitivity. Comparison of
spectra from LOV2 and cyan, yellow and red proteins suggests
potential RET in all cases (Supplementary Fig. 1). Consequences
could include sensitised actuation by cyan proteins, suppressed
actuation by yellow and red proteins or no effect (Supplementary
Fig. 2).
Determining the influence of fusion tags requires an assay to
quantify LOV2 switching. The optogenetic nuclear translocator
LEXY interweaves a NES with the AsLOV2-Jα helix9, providing a
convenient actuation readout. Light-induced unfolding of the Jα
exposes the NES, increasing nuclear export until LOV2 relaxation
terminates NES exposure9. We generated a panel of such
constructs using different fluorescent tags (XFPs, Supplementary
Figs. 3–4). Because of a minor sequence difference, we refer to
these as optoNES to avoid possible confusion with the original
LEXY9. We only consider light sensitivity rather than dynamic
range of translocation; these are independent parameters just as
enzyme Km and Vmax are independent. Hippocampal neurons
infected with AAVs encoding XFP-optoNES (Supplementary
Fig. 4) show localisation to nuclear and cytoplasmic compart-
ments, but translocation out of the nucleus in response to light
(Fig. 1a, b; Supplementary Fig. 5 and Supplementary Movies 1–6).
To quantify light sensitivity, we provided cycles of ten light
pulses, each partially switching the LOV2 domain. Translocation
rate is quantifiable by fluorescence imaging (Fig. 1a–d). Four
cycles were applied at each of four 438 nm photon doses, between
~14 and 420 µmol m−2 flash−1 (1 µmol m−2 s−1= 27 µW cm−2;
Fig. 1c). Sensitivity was calculated from the nucleocytoplasmic
ratio change per flash for each dose (Fig. 1e and Supplementary
Fig. 6). Under these conditions, all constructs exhibited light-
dependent nuclear export. But the mTurquoise2 fusion was
notably more sensitive to blue light than the other fusion
constructs (Supplementary Table 1).
To determine whether these differences result from RET, we
separated fluorophores and LOV2 domain with 24 residues
(Supplementary Fig. 7), increasing inter-dipole distances to which
RET efficiency is exquisitely sensitive (6th power relation,
Supplementary Fig. 1A). Excess positive charge in the spacer
should favour an extended confirmation, but even a random-coil
conformation (with residue spacing of 0.38 nm10) would add 1.9
nm. Generously estimating initial inter-dipole distance at 5 nm, a
typical value for R0, this equates to 1.4-fold distancing and a
minimum sevenfold reduction of RET ([R/R0]6).
These reduced-RET optoNES variants export with indistin-
guishable sensitivity (Fig. 1f and Supplementary Fig. 8). Thus, the
spacer increased sensitivity where LOV2 can act as a donor
(approximately threefold for Ypet or mScarlet constructs) and
reduced sensitivity of the mTurquoise2 construct >twofold
(Fig. 1e–h and Supplementary Table 1). To evaluate whether
differences in fusion protein sequences, and not RET, could be
responsible for sensitivity differences, we replaced the constitu-
tively fluorescent proteins with reversibly photoswitchable
protein Dronpa. This protein can be switched between 400 nm
absorbing and yellow fluorescent protein-like states11 (Supple-
mentary Fig. 9A). Thus we compared actuation sensitivity using
the same protein in either a dark or Ypet-like fusion (competent
to act as a RET acceptor), and latter form showed significantly
less sensitivity to light (Fig. 1i).
These results indicate engineering RET into optogenetic
actuators can either increase or decrease sensitivity. In the
specific case that a red fusion protein, commonly used in
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Fig. 1 Fluorescent protein tags strongly influence the sensitivity of LOV2-based optogenetic nuclear export. a Blue-light induces export of mTurquoise2-
tagged optogenetic nuclear export construct, mTq2-optoNES (Supplementary Fig. 4) in hippocampal neurons (n= 8 wells at 40× magnification, scalebar
10 µm; other examples in Supplementary Fig. 5). b Fluorescent protein tags (XFP) fused to optogenetic constructs might influence their sensitivity to light
via RET. c Illumination scheme used to quantify light-dependency of nuclear export rates. d Example data from a single 10× field treated as shown in c (four
cycles, at least 10 min apart, mean ± SEM, for 23 and 31 cells, respectively), showing faster export at higher photon flux. e Nuclear export rate dependence
on photon flux is shown for optoNES constructs fused to fluorescent proteins mTurquoise2, Ypet and mScarlet (in turquoise, yellow and red, respectively)
expressed in different cultures. The mTq2 construct is more sensitive (significant by F-test, F(2,66)= 41.34, P < 0.0001). Data are normalised to fitted
maximal rates to facilitate sensitivity comparison (non-normalised versions in Supplementary Fig. 9). f Corresponding experiments with a spacer between
fluorescent protein and LOV2 domain to reduce resonance energy transfer (RET, Supplementary Fig. 8). All constructs are equally sensitive to light, thus in
e, mTurquoise had increased sensitivity whereas Ypet/mScarlet decreased sensitivity. This suggests RET can either increase or decrease optogenetic
switch sensitivity. In e-f, all channels were imaged regardless of which XFP was used, to ensure identical illumination conditions. Data are means ± SEM,
n= 6 wells. Best-fit ED50s in µmol 438 nm photons.m−2.flash−1 indicated on the graphs for clarity and in Supplementary Table 1 with standard errors.
g Introduction of RET-limiting spacer reduces sensitivity (ED50) of the mTq2 optoNES >twofold; F-test, F(1,44)= 10.33. h Corresponding sensitivities for
the Ypet and mScarlet optoNES (from e to f) showing introduction of spacer to limit RET increases sensitivity >threefold; F(1,44)= 23.19 and 49.86, for
Ypet and mScarlet respectively; i Dronpa-optoNES shows significant difference in sensitivity in Dronpa-off and Dronpa-on states; F(1, 45)= 49.51. g–i show
best-fit values ± S.E. (**P= 0.0025, ***P < 0.0001) from curve-fitting of datasets in e, f and Supplementary Fig. 9F. Source data are provided as a Source
Data file.
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optogenetic actuators, is replaced with a cyan one, a sevenfold
sensitivity increase may be achievable.
Direct visualisation of LOV2 switching in intact cells. RET
from donor to LOV2 acceptor should quench donor emission
(Fig. 2ai, left). Absorption of a photon by the ground-state (LOV-
445) leads with high probability to formation of the triplet state
LOV-660T within 2 ns. This subsequently forms the cysteine
adduct LOV-39012, which exhibits >50% lower absorption com-
pared with LOV-44513. RET to LOV2 should fall, resulting in
measurable dequench of mTurquoise2 (Fig. 2ai, right). LOV-390
formation causes an immediate (~10 µs12) partial unfolding of
AsLOV2 flanking regions, via a glutamine lever mechanism acting
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on both C-terminal Jα and N-terminal A’ α helix14. Slower
(250 µs12) and complete undocking of Jα follows12,15, resulting in
the order-disorder transition used to generate actuation in
optogenetic tools1. This N-terminal A’ helix unfolding reduces
fluorescent tag-FMN proximity, contributing a second RET-
limiting mechanism as LOV2 switches (Fig. 2ai).
As predicted, mTq2-optoNES emission increased during
exposure to 438 nm light (Fig. 2b and Supplementary Fig. 10),
revealing an initial quench (20% more than after equilibrium
switching in intact cells; Fig. 2b, c). In contrast, the reduced-RET
version (Fig. 2Aii and Supplementary Fig. 7) exhibited less
dequenching (Fig. 2b–e). Dequenching is therefore sensitive to
the relative placement of mTurquoise and LOV2 domains,
consistent with RET. Nevertheless in both constructs, LOV2
domain-activating blue-light dequenches fused mTurquoise.
Thus, dequenching curves indicate the switching of the LOV2
domain in intact cells. LOV2 switching has previously only been
measured by photobleaching purified proteins in a cuvette. We
can now infer the apparent sensitivity of activation from
dequenching rate. Half-maximal de-quenching took ~1.3 s (5
readings, total ~140 µmol m−2 photons). Such a fast de-quench
half-time may estimate in situ activation rate if cell-free LOV2Jα
relaxation rates (~20–80 s6,16,17) are applicable and counteracting
relaxation can be neglected.
We estimated dequenching limits and activation rates more
directly with rounds of activation at different photon intensities,
fitting data to exponentials to extrapolate pre-illumination and
final intensity levels (Fig. 2c, d). Dequenching-dose curves
(Fig. 2e) provide estimates of dequenching limit (i.e. in the
absence of relaxation, as photon dose approaches infinity) and
ED50 (photon dose that, at equilibrium, achieves half-maximal
dequenching i.e. photoswitching). The entire data was also fitted
to a first order reversible kinetic model (Fig. 2f), providing rate
constants (Fig. 2g, h, for activation, 1/k1 ~200 µmol m−2; for
relaxation 1/k−1 ~5 s) and additional estimates of dequench limit
and ED50 (Fig. 2i, j). The activation sensitivity is comparable to
observations in cells6. However, derived optoNES relaxation rates
in situ were considerably faster than anticipated from cell-free
spectroscopic measurements of LOV2Jα proteins3,6. This not only
limits accuracy of the activation rate estimate shown in Fig. 2b
but also has significant relevance for experimental use of LOV2-
based optogenetic actuators.
Visualisation and direct quantification of LOV2 relaxation.
The cysteine-adduct LOV-390 also absorbs activation wave-
lengths (425–475 nm). An unexpectedly short relaxation time
during repeated light flashes (Fig. 2h) could potentially result
from photochemical back-reactions16. Moreover cell-free LOV2
relaxation measurements showed a strong influence of tempera-
ture6, and Jα modifications used to generate some optogenetic
actuators8. We therefore sought a simple direct method to
determine relaxation time in situ in darkness, as accurate
knowledge of relaxation rates within experimental settings is
required to design illumination protocols.
The experimental paradigm used in Fig. 2b, in which
dequenching reveals the protein fraction in activated state, can
be repeatedly followed by defined periods of darkness. This shows
that the duration of darkness determines loss of activated fraction
(Fig. 3a–c), thereby revealing the relaxation rate of the LOV2-
based actuator in intact living cells (Table 1a). The experiments
confirmed that optoNES construct relaxation rates are indeed
shorter than values obtained by cell-free spectroscopy of LOV2Jα
(tau 6–7 s vs. ~80 s3). The rates in darkness are slower than those
derived from dequenching curves under repeated illumination
(Fig. 2h), consistent with a photochemical back-reaction when
LOV-390 absorbs blue light16. Regardless, a consistent conclusion
from Figs. 2–3 is that actuators in intact cells relax much faster
than expected from cell-free spectroscopy of LOV2, even when
temperature is taken into account6,16.
The activation-relaxation paradigm in Fig. 3 provides a true
relaxation rate (reverse rate constant) but only an apparent
activation sensitivity (forward rate constant), which under-
estimates the true sensitivity (Table 1a) due to the concurrent
relaxation. However, based on first order reversible kinetics
(Fig. 2e) the forward rate constant (sensitivity), dequench limit
and photon dose required to achieve 50% maximal switch
equilibrium (ED50) can easily be calculated from fitted parameters
(see methods). Therefore we primarily use the activation-
relaxation approach and derived the missing parameters by
curve-fitting.
Optimisation of RET and sensitisation. Just as RET is reduced
by increasing mTurquoise-LOV2 distance, removing sequence
between mTurquoise and LOV2 could increase RET. RET from
mTurquoise2 doubles actuation sensitivity (Fig. 1g) and promotes
LOV2 switching (Fig. 2g), allowing real-time activation/relaxation
detection in living cells. We asked if RET could be further
increased. A more photosensitive actuator could be switched
more frequently and used for longer experiments with less pho-
totoxicity. More sensitive detection permits more precise and
frequent monitoring of actuator state.
Fluorescent protein structures reveal C-terminal residues
outside the core beta-barrel structure. Deleting these residues
can generate up to 95% RET in some applications18. We
generated an mTurquoise2 deletion series lacking 7–11 C-
terminal residues (Fig. 4a) fused to LOV2 residue 408. This
Fig. 2 Dequenching of mTurquoise2 as a measurement of LOV2 activation. a (i) LOV2 domain-fused mTq2 can act as a RET donor and transfer energy to
FMN in the adjacent domain, and is partially quenched. Once LOV2 is activated directly or via RET, formation of FMN-adduct changes the absorption
spectrum, reducing its ability to act as a RET acceptor. The LOV2 domain A’α helix extends, placing the FMN and LOV2 domain further from the
fluorescent protein, also reducing RET. Thus mTq2 becomes dequenched; (ii) Placing a spacer between mTq2 and the LOV2 domain reduces RET from the
outset, limiting initial quenching and the corresponding dequenching on LOV2 activation. b Changes in fluorescence emission of mTq2 fusion proteins,
mTq2-optoNES, and mTq2-spacer-optoNES (Supplementary Fig. 8) expressed in HEK293 cells, are observed during 50 flashes of 14 µmolm−2 438 nm
light at ~4 Hz. This replicate illustrates LOV2-dependent dequenching, with exponential fits yielding decay constants of 0.12 and 0.13 per flash i.e. τ ~8 s and
differing levels of maximal dequench (or initial quench, A0); c, d Means ± SEMs (n= 3 wells) of samples as shown in b were exposed to photon doses per
438 nm flash as indicated. Dequenching curves were corrected in all cases to the signal from a parallel free mTurquoise2 sample exposed to identical
illumination conditions (Supplementary Fig. 10), normalised to the first data point and then plotted against flash number. Data were fitted to exponentials
to derive fluorescence prior to illumination, maximum fluorescence and rate constants. e Data from c, d, fitted to exponentials, show the relation between
maximal dequench and photon dose. Fitting to a single site model provides estimates of dequench limit i.e. the extent to which the Tq2 is originally
quenched, and ED50 the photon dose/flash to achieve half this dequenching at equilibrium when delivered at ~4 Hz. f All data points were fitted to a first
order reversible kinetic model, providing more reliable estimates of g sensitivity (1/k1), h relaxation time constant during illumination, i Dequench limit and
j ED50. ***n.s. indicate significant difference (P < 0.0001) and no significant difference by unpaired one-tailed multiple t-test with Holm–Sidak correction.
Source data are provided as a Source Data file.
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truncates the A’ helix that participates in Jα regulation but not the
photocycle17. Confirming Jα perturbation, the NES21 motif is at
least partially exposed as dC11-408LOV2-NES21 is mostly
cytoplasmic (Fig. 4b), although the 408LOV2 can still optically
regulate heterologous targets19. The deletions increase maximal
dequench compared with the original mTq2-optoNES (Fig. 4c, d,
Table 1a, and Supplementary Figs. 11–12). Directly fitting the
entire dataset to a formula cast in terms of quench limit,
sensitivity and relaxation rate, indicates the true initial quench of
mTurquoise is as much as 24% (relative to LOV-390, Table 1a).
Sensitivity and dequench limit show significant correlation
(Fig. 4e, Supplementary Fig. 12, and Table 2). The dC7 construct
has the highest RET and sensitivity (lowest value in µmol m−2),
suggesting further deletion either increased dipole distance or
introduced unfavourable dipole angles and RET failed to increase.
Nevertheless, increased RET allows optogenetic switching with
fewer photons compared with the parental mTq2-optoNES
construct.
Determinants of relaxation rate. The relaxation mismatch
between actuators in situ and reports for cell-free purified
recombinant LOV2 is evident, but the cause is not. One factor is
temperature6,16, another is Jα editing8. The constructs in Fig. 4
have the same Jα sequence and fluorescent tag, yet in situ they
exhibit threefold different relaxation rates (Table 1a). This sug-
gests the tag-LOV2 linker can also have considerable impact.
Although this potentially complicates interpretation of Fig. 1f
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Fig. 3 Direct quantification of relaxation time as recovery from dequenching of mTurquoise by LOV2. a Illumination strategy to map LOV2 switching
(changes in quenching) during illumination and relaxation-induced dequenching in darkness. Samples were exposed to 20 flashes (14 µmol/m2 438 nm) at
~4 Hz followed by 1–180 s darkness. b HEK293 cells expressing mTq2-optoNES (blue symbols) or mTq2-spacer-optoNES (red symbols) were imaged
during the flash sequence as in a to induce dequenching followed by 12 sequentially increasing dark periods, allowing relaxation. The whole 240 image
sequence was repeated three times per sample to reduce noise. Responses from each segmented cell (region of interest) in the field and from each repeat
were averaged. All wellwise-averaged data from transfected cells are normalised to an average of replicates for a corresponding mTurquoise-expressing
sample (without LOV2) exposed to the same illumination conditions (Supplementary Fig. 10). Means are plotted against reading number. Each
dequenching phase was fitted to an exponential as in Fig. 3, with independent size and common activation rate constant for each protein, providing offset
and amplitude estimates for each cycle. These curves, together with the dark-phase changes are shown as a solid line between the data points, showing
goodness of fit. Apparent activation rate constants at this photon flux were 0.12 and 0.11 per flash, equivalent to a photon sensitivity of 115 and 131 µmol/
m2. c The same data as in b is plotted against reading number to more easily visualise the responses. Each grid-line represents an increasingly long dark
period as shown in a, b. d The quench recovery estimated from the exponential curve fits in b/c, is plotted against the duration of dark time causing the
quench. This reveals the time-dependence of recovery from dequenching. The data is fitted to an exponential to derive relaxation time constants (~7 s for
both constructs) and dequenching maxima. As evident from b and c, the dequenching is at maximum ~19 and 5% of initial fluorescence for mTq2-optoNES
and the spacer construct respectively. Source data are provided as a Source Data file. Data are presented as means ± SEM; n= 6 wells for mTq2-optoNES
and n= 5 wells for mTq2-spacer-optoNES.
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where RET is limited with a spacer, Fig. 2 showed the spacer used
did not affect relaxation rates. Whether the cellular environment
also influences relaxation is unclear. We compared in situ
relaxation rates with those determined in cell-free HEK293 lysates
at different temperatures (Fig. 4f). This confirms the impact of
temperature but, for the actuators tested, shows no evidence for
contributions of the cellular environment per se (Fig. 4f).
In situ photocycle monitoring generalises to other actuators.
Could activation-relaxation cycling report in-cell sensitivity and
relaxation of other optogenetic actuators? We selected optoJNKi,
an optimised JNK inhibitor design that revealed resonance in
JNK signalling circuits6 and JNK regulation of dendritic spines20,
and similar p38 inhibitors, optop38i3 and optop38i56. All acti-
vatable constructs generated dequench-recovery cycles (Fig. 5a,
b). The LOV2 mutant optoJNKi-C450A (aka dark state mutant,
or optoJNKi.dsm6) binds FMN but lacks the cysteine that forms
the FMN-adduct and cannot photocycle21. No FMN-adduct can
be formed and thus RET should not change. We observe no cyclic
dequenching-requenching (Fig. 5a).
Relaxation times are again shorter than expected from cell-free
spectroscopy (Fig. 5c and Table 1a), even comparing to His-
tagged optoJNKi at 37 °C6, consistent with an influence of N-
terminal linker. These constructs have intact Jα (to residue 546)
unlike optoNES and LEXY (to residue 541 only), and have longer
relaxation times, consistent with Jα modification hastening
relaxation8. The best-fit dequench and sensitivity parameters for
these actuators map above the sensitivity-FRET (dequench limit)
relation of optoNES constructs with modified Jα (Fig. 4e and
Supplementary Fig. 12), again consistent with a stable Jα.
Photocycle monitoring generalises to other fluorophores. In
situ determination of activation and relaxation rates requires a
RET-competent tag like mTurquoise (Figs. 2–5). Figure 1 shows
RET also occurs with yellow and red proteins, and presumably
any protein having spectral overlap with LOV2. Substituting
mTurquoise with Ypet showed a larger RET effect (Fig. 6; quench
limit up to 66%, Table 1a), consistent with greater spectral
overlap (Supplementary Fig 1). As LOV* acts as a donor here,
Ypet emission upon 438 nm excitation is initially enhanced
(approximately twofold, Fig. 6a) but each flash converting LOV-
445 to LOV-390 reduces Ypet emission, consistent with RET loss,
thus traces are inverted compared with Figs. 2–5. A dark period
recovers the sensitised Ypet signal. Activation and relaxation
parameters can be obtained from Ypet-LOV2 fusions (Fig. 6e–g
and Table 1a). RET from LOV2 to Ypet causes loss of energy
from S1-state LOV* and activation sensitivities are >fivefold
lower than mTurquoise2 versions. The RET-limiting spacer
(Fig. 1 and Supplementary Fig 8) reduces dequench limit. This is
the opposite of the mTurquoise2 constructs, consistent with Ypet
acting as acceptor. Red protein mScarlet has similar effects to
Ypet (Supplementary Fig 13 and Table 1a). This is predictable
Table 1 Properties of constructs examined in this study determined by resonance energy transfer.
Actuator Maximal dequench or
quench1 (% of Flimit)
Apparent activation
rate2 (µmol m−2)
Relaxation time
constant in
dark3 (s)
ED450 (µmol m−2) Dequench or
quench limit5 (%)
Sensitivity6
(µmol m−2)
A
mTurquoise2 fusions
optoNES 15.9 ± 0.3 115 ± 5 6.8 ± 0.6 5.78 ± 0.22 18.9 ± 0.2 162 ± 4
spacer-optoNES 4.6 ± 0.1 131 ± 18 7.2 ± 1.1 6.41 ± 0.77 6.5 ± 0.2 192 ± 15
dC7-408LOV2-NES21 25.7 ± 0.8 121 ± 7 11.5 ± 1.5 2.24 ± 0.29 23.6 ± 0.4 124 ± 8
dC8-408LOV2-NES21 20.1 ± 0.6 134 ± 2 12.4 ± 1.6 2.29 ± 0.07 19.3 ± 0.1 137 ± 2
dC9-408LOV2-NES21 16.9 ± 0.6 148 ± 4 13.3 ± 2.1* 2.20 ± 0.13 16.6 ± 0.1 146 ± 4
dC10-408LOV2-NES21 23.3 ± 0.8 148 ± 9 17.2 ± 2.3* 1.77 ± 0.2 21.2 ± 0.3 146 ± 8
dC11-408LOV2-NES21 21.1 ± 0.6 122 ± 7 11.0 ± 1.3 2.57 ± 0.33 20.4 ± 0.4 130 ± 8
optoJNKi wt 16.1 ± 0.6 163 ± 10.9 13.7 ± 1.8 3.7 ± 0.5 17 ± 0.5 206 ± 18
optoJNKiC450A n/a n/a n/a n/a n/a n/a
optop38i3 16.4 ± 0.6 162 ± 5.9 13.8 ± 1.8 3.7 ± 0.3 17.2 ± 0.3 204 ± 10
optop38i5 16.9 ± 0.6 163 ± 5.1 14.4 ± 1.8 3.5 ± 0.2 17.6 ± 0.3 203 ± 9
Ypet fusions
optoNES 54.5 ± 0.8 493 ± 9 8.0 ± 0.5 18.6 ± 1.1 53.5 ± 0.7 559 ± 12
spacer-optoNES 29.8 ± 1.1 430 ± 65 7.6 ± 1.4 15.9 ± 7.4 33.2 ± 3.7 479 ± 83
optoJNKi 65.6 ± 0.9 785 ± 4 23 ± 1.1 10.1 ± 0.1 60.4 ± 0.2 843 ± 5
mScarlet fusions
optoNES 39.4 ± 0.8 1140 ± 159 7.2 ± 0.7 58.3 ± 22.7 53.2 ± 2.1 1619 ± 348
spacer-optoNES 51.9 ± 0.8 955 ± 5 7.3 ± 0.5 44.7 ± 0.9 64.2 ± 0.2 1263 ± 12
optoJNKi 61.7 ± 1.6 1315 ± 33 15.5 ± 1.6 28.9 ± 1.6 68.8 ± 0.5 1594 ± 49
Actuator (Ypet fusion
with LOV2 mutation)
Max quench at 140
µmol m−2 (% of F0)
Apparent activation rate
(µmol m−2) at 140 µmolm−2
Relaxation time
constant in situ (s)
Relaxation time constant
reported cell-free (s)
B
optoNES wt 57.4 ± 1.0 492 ± 5 7.6 ± 0.62 80 (Zoltowski et al. [23])
optoNES V416I 54.1 ± 1.6 584 ± 7 84.1 ± 4.7 821 (Zoltowski et al. [23])
optoNES I427V 28.2 ± 0.6 272 ± 9 0.81 ± 0.14 6 (Zayner et al. [3])
optoNES F434L 23.8 ± 1.0 237 ± 8 0.58 ± 0.25 12 (Zayner et al. [3])
Values shown are estimated best-fit ± standard error from curve fitting as described in the methods.
1. Maximal dequench or quench—this is the equilibrium impact on emission from the fluorescent protein on repeated illumination with 438 nm light (cf Fig. 2e). It is caused by resonance energy transfer
to or from the nearby LOV2, but the equilibrium point depends also on continuous relaxation. For this reason the value depends on the rate (~4 Hz) and intensity of 438 nm light flashes, which is
indicated. mTurquoise2 fusions were dequenched at 14 µmol m−2 whereas Ypet and mScarlet fusions were less sensitive and were quenched at 140 µmol m−2.
2. Apparent activation rate is the measure of apparent sensitivity of switching, again influenced by concomitant relaxation and dependent on photon flux, which is indicated for each group. mTurquoise2
fusions were activated at 14 µmol m−2 whereas Ypet and mScarlet fusions were less sensitive and were activated at 140 µmol m−2.
3. Relaxation time in darkness is calculated from periods of darkness and is independent of activating photon flux. In Table 1B, the measured values of relaxation mutants in the optoNES context are
compared to literature values of recombinant cell-free LOV2 mutant without actuator or fluorescent protein fusion.
4. ED50 is the estimated photon dose at the rate used (~4 Hz) predicted to achieve half-maximal switching at equilibrium, taking concomitant relaxation into account.
5. Dequench or quench limit—this is the estimated relaxation independent of maximal possible quench (for acceptors Ypet and mScarlet) or dequench (for mTurquoise2).
6. Sensitivity is the estimated sensitivity value in the absence of relaxation derived from curve fit formulae that take the concomitant relaxation rate into account.
An asterisk denotes statistically significant difference in relaxation between optoNES and dC9 (P= 0.0364) and dC10 (P= 0.0004), and spacer-optoNES and dC10 (P= 0.001) constructs by one-way
ANOVA and post-hoc Tukey test. No other significant difference was found among the mTurquoise-optoNES construct in situ relaxation rates.
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given the spectral overlaps (Supplementary Fig. 1) and the longer
wavelength proteins acting to limit LOV2 responsiveness. Dark
state relaxation times, a thermal process of adduct decay, are
generally insensitive to the fused fluorescent tag (Table 1a), in
contrast to the strong effects of the linker sequence. However
exceptions exist, as Ypet-fused optoJNKi has an unusually long
relaxation time.
Parameter-based minimisation of light dose for actuation. The
parameters applied allow prediction of activated state dynamics of
the actuator during illumination trains, even if it does not
translocate or provide visual cues of activation. The optoJNKi
fraction in adduct state (LOV-390) reduces rapidly after each
activating light flash (relaxation time-constant of 14–23 s,
Table 1a), so frequent illumination is required to maintain acti-
vated optoJNKi. The imaging-based translocation reporter
JNKktr22 allows us to determine JNK inhibition during a given
illumination pattern. We aimed to efficiently stimulate optoJNKi
by repeated illumination while simultaneously quantifying inhi-
bition of the JNK pathway in multiple samples. Sequential peri-
odic epi-fluorescence imaging in multiple samples was paired
with parallel optoJNKi activation by a multiwell trans-illuminator
device (Fig. 7a). We predicted adduct state levels over time
(Fig. 7b), based on activation and relaxation parameters deter-
mined for mTq2, Ypet and mScarlet-optoJNKi (Table 1a).
Extremely low photon fluxes (60 µW cm−2= 2.3 µmol m−2 s−1,
for 1 s every 7.5 s) were selected to avoid detectable long-term
effects on gene expression or toxicity even under media-enhanced
phototoxic conditions2. The peak adduct state fraction was pre-
dicted to be <3% before each decay in the case of mTq2-optoJNKi
(Fig. 7b). Once LOV2-445 is regenerated, there will be a delay
before the construct dissociates and the target becomes available
for interaction with substrates. The adduct state fraction is
therefore an underestimate of the optogenetic inhibitors capable
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Fig. 4 Increased RET to LOV2 and sensitisation can be achieved by linker optimisation. a Alignments of XFP-optoNES variants compared with the
original mCherry-fused LEXY9, showing the end of the fluorescent protein βbarrel and intervening sequences. AsLOV2 starts at leucine 404 or trimmed to
408 to increase RET; b The trimmed constructs are typically constitutively cytoplasmic because disruption of A’α helix by deleting LOV2 residues
404–407 renders the constructs functionally active as expected (the dC11 construct is shown; scalebar 20 µm, n= 3 wells in ×10 magnification, 1 example
imaged at ×40); c The C7-C11 deletion series of mTq2 fused to 408LOV2-NES21 were subjected to kinetic RET analysis, revealing characteristic dequench-
relaxation cycles (mean, n= 3; SEM shown in Supplementary Fig. 11); d Analysis of the dequench-relaxation as in Fig. 3 reveals that deletion of linker can
almost double maximal dequench (at 14 µmol m−2) though relaxation rate is also affected. The dC7 construct has least deletion but greatest dequench,
suggesting dipole angles or other parameters reduce RET in other constructs though mTq2-LOV2 distance in primary sequence is reduced. Best-fit
parameters—maximum dequench, apparent sensitivity, relaxation time and ED50, dequench limit and sensitivity are compared in Table 1A. e Activation
sensitivity of the mTurquoise-optoNES constructs from Table 1A correlates with dequench limit (equivalent to effective FRET efficiency; statistical analysis
in Supplementary Table 2, best-fit ± S.E., n= 3 wells). f Best-fit relaxation rates obtained from the in situ data (green bars; Table 1A) are shown together
with the corresponding values derived from measurements performed on lysates of cells expressing the same constructs (dC7, dC10, dC11 and the parental
optoNES) at 25 and 37 °C (blue and red bars). This shows that temperature has a strong influence on relaxation rates of these constructs but, when the
sequences used are identical, there is no significant difference between relaxation in intact cells and the cell lysates in any case. Mean ± standard error is
shown (n= 8 cell-free, n= 6 and 3 for in-cell wild-type and variants respectively). *, **, *** denote P < 0.05, 0.01, and 0.0001, respectively (25 °C
compared to either of the 37 °C values) by Tukey post-hoc test after two-way ANOVA. n.s. not significant. Source data are provided as a Source Data file.
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of binding targets. Nevertheless a clear difference between
mTurquoise2, Ypet and mScarlet versions is predicted as we likely
avoid saturation of targets. These illumination conditions caused
significant light-dependent inhibition by mTq2-optoJNKi, mini-
mal light-dependent effect of Ypet-optoJNKi and no discernible
impact of light on mScarlet-optoJNKi infected neurons
(Fig. 7c–f).
This demonstrates the generality of the optoNES findings
(Fig. 1), that sensitivity of optogenetic actuation under linear
illumination conditions can be modulated by fluorescent fusion
tags. It also demonstrates that in situ RET-derived activation and
relaxation parameters aid the selection of minimal illumination
conditions sufficient for switching (and hence actuation). This
means that, when using optogenetic actuators, the blue-light
toxicity artefacts can be limited even in long-term studies, and the
likelihood of achieving intended outcomes is increased even
where on-line validation assays are not available.
RET guides optimisation of in situ relaxation time. Relaxation
of all optogenetic constructs tested in situ is consistently faster
(up to tenfold) than for recombinant LOV2 measured by absor-
bance spectroscopy. This mismatch complicates the application of
cellular optogenetics. For example, the high-frequency (0.13 Hz)
illumination required (Fig. 7), if delivered through-the-objective,
greatly limits throughput. Parallel trans-illumination devices
(Fig. 7a), in providing an illumination path orthogonal to the epi-
fluorescence microscope optical path, can resolve the sample
throughput bottleneck. But rapid relaxation time also means
higher blue-light doses are required to maintain switching (and
hence actuation).
For these reasons we turned to relaxation-time mutants of
LOV2. The impacts of mutating V416, I427 and F434 and others
on decay rate of the FMN adduct and therefore relaxation times
have been reported by cell-free spectroscopy3,23, and in some
cases impact on downstream actuation has been quantified in
intact cells24,25. However the effect of these mutations on actual
state-switching of LOV2, independent of actuation-specific
complexities, have not previously been measured in situ. The
LOV2 FRET-based in situ switching assay shows that LOV2-
V416I slows Ypet-optoNES relaxation rate approximately tenfold
whereas I427V and F434L mutants both show ~20-fold faster
relaxation (Fig. 8 and Table 1b). These fold-changes are
consistent with spectroscopic data using AsLov2 without Jα
modification, but optoNES in situ time constants are 10- to 15-
fold faster3,23.
Re-programming and quantifying signalling pathway dynam-
ics. A slower-relaxing optoJNKi would allow simpler and more
efficient experimentation than in Fig. 7. mTq2-optoJNKi-sr (slow
relaxation), incorporating the V416I mutation, has a relaxation
time of ~2 min (Supplementary Fig. 14), 7 times slower than the
original optoJNKi (Table 1a) and is the most sensitive construct
tested (lowest ED50). We compared the applicability of optoJNKi
variants to regulate neuronal JNK pathway activation by pacli-
taxel and vincristine, clinically used chemotherapeutic agents
associated with central neurotoxicity26–28.
In a traditional through-the-objective actuation configuration
—where imaging and actuation light use a common epi-
fluorescence path—optoJNKi requires five flashes per min to
suppress JNK activity (Fig. 9a–c), precluding parallel sample
imaging. Response modulation is gradual (tau ~4–16 min),
demonstrating the requirement for continued inhibition to
modify the response. In contrast, 0.5 flashes per min is sufficient
for optoJNKi-sr to rapidly suppress the JNK pathway (Fig. 9d, e).
This permits multi-sample imaging, >tenfold increased through-
put, and JNK inhibition with tenfold less blue light. Under these
conditions, neurons tolerate repeated long-term modulation of
the pathway (Fig. 9e).
Selection of a LOV2 mutant with in situ response times
matching target kinetics (JNK regulation) simplifies optogenetic
modulation of the JNK pathway. Although JNKktr requires
nuclear-cytoplasmic translocation to report a change, measured
translocation rates (tau 1.8–2.8 min22) are considerably faster
than response rates seen here (Fig. 9f). Light-evoked inhibition of
reporter is threefold faster than recovery in darkness 20 min later
(Fig. 9d, f). This suggests phosphatases act more rapidly than
kinases on the c-Jun derived reporter in this condition, and
reporter translocation cannot explain this discrepancy. In Fig. 9e,
JNK is inhibited considerably longer and the difference is greatly
diminished (Fig. 9f). This reveals significant differences in re-
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activation rates between the two conditions but no difference
between inactivation rates (Fig. 9f). This could reflect negative
feedback on the JNK pathway, whereby persistent inhibition of
substrate phosphorylation by optoJNKi-sr in Fig. 9d results in
higher activity, leading to more rapid recovery of the reporter
response in Fig. 9d. This data alone does not discriminate
between changes in kinase or phosphatase activities. Subsequent
recovery in all cases to about the same level (as prior to
inhibition) argues either for balanced changes in both or a rapid
return to the initial balance, but more experiments would be
needed to distinguish these possibilities. Nevertheless, this shows
tools like optoJNKi can be optimised to repeatedly inhibit and
release a target in an efficient contact-free manner with minimal
illumination. Traditional inhibitor approaches do not allow this
longitudinal approach, multiple parallel samples would be
required. Moreover penetration, distribution, washout and turn-
over rates of inhibitors, together with the stressful effects of cell
washing, introduce further complications. In contrast, optoJNKi-
sr permits a highly versatile and repeatable in situ probing of
pathway dynamics from single samples at multiple time-points
during a response.
Discussion
Optogenetic approaches have revolutionised behavioural neu-
roscience. Implementation in cell biology and related fields has
also been impressive but limited to relatively few labs. It remains
challenging to develop and use optical regulators of biochemical
processes. One difficulty is the inability to directly monitor the
switched state of optogenetic actuators. The vast majority of
cellular optogenetic actuator studies generate easily visualised end
points, such as protein translocation and cell motility9,24,29–32,
where cellular outcomes can be directly verified. This is a pow-
erful approach when activation of signalling is achieved by
changes spatially tethered to a membrane compartment, for
example24,33,34. However, many targets are not constrained to
easily visualised loci. This problem is compounded by invisible
spontaneous relaxation of actuators to the inactive dark-state.
Relaxation rate has been measured in cell-free conditions but not
in intact biological systems. Optogenetic inhibitors of endogenous
delocalised activities—the optogenetic equivalent of pharmaco-
logical tools—are particularly rare because indirect methods are
generally required to validate their actions. Optogenetic activators
can be straightforward to implement for proof-of-concept in
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model cell lines. However, inhibitors of endogenous signalling
processes can be more valuable tools to investigate physiological
mechanisms than imposition of overexpressed synthetic activity.
Moreover, biological end-points of interest may require main-
tenance of actuation for prolonged periods of time, unlike the
milliseconds of activation in channelrhodopsin applications. For
popular blue-light photosensors, using endogenous flavins rather
than exogenous chromophores like phytochromobilin, this is an
additional challenge because even low doses of blue light can
perturb biological systems in the long term1,2.
Building on the easily visualised responsivity of LEXY9, the
light-regulated NES, we found sensitivity could be doubled by
engineering RET from a cyan fluorescent donor (Fig. 1e). Con-
versely red and yellow proteins act as RET acceptors, reducing
sensitivity ~3.5-fold (Fig. 1 and Supplementary Table 1). Sensi-
tivity can be dynamically tuned with a photo-switchable protein.
This potentially opens the door to multiplexing, whereby ortho-
gonal inputs (non-blue light) determine which actuator present
will respond to blue light. Linker optimisation increases energy
transfer from the cyan protein (Fig. 4 and Table 1a), potentially
further sensitising actuation (Fig. 4e). The finding that fluorescent
tags modulate activation under linear illumination complements
previously described mutational tuning of LOV2 relaxation
time3,35. Combining control of both activation and relaxation
rates offers precise blue-light activated cellular optogenetic
design. Long-term experiments, with considerably more optoge-
netic manipulations, become possible before blue-light photo-
toxicity becomes limiting. If fewer photons are required to
activate LOV2, improving temporal resolution with faster relax-
ing LOV2 mutants becomes possible.
Sensitisation of flavin-based optogenetic switches under non-
linear illumination (two-photon microscopy) was recently descri-
bed36 using mtagBFP and mTFP1 for CRY2 and LOV2 respec-
tively. Sensitisation was not seen in wide-field mode, perhaps
because mtagBFP2 and mTFP1 are less suitable than mTurquoise2
for FRET. We predicted limited overall RET between mTFP1, with
characteristics mid-way between mTurquoise2 and Ypet, and
LOV2 (Supplementary Fig. 15A, B). In practice, mTFP1 performs
poorly as an indicator of AsLOV2 state compared with mTur-
quoise2 or Ypet (Supplementary Fig. 15C–E). Under two-photon
microscopy, two photons are absorbed within a short time, and the
higher absorbance of mTFP1 than AsLOV2 becomes the dominant
factor under non-linear conditions. Under more commonly used
linear excitation, we found mTurquoise2 offers at least twofold
increased optogenetic sensitivity.
A second consequence of RET in LOV2-based tools is that the
photocycle, i.e. optogenetic actuator switching, can be generically
monitored in situ because this influences fluorescent tag
quenching. Note this does not report the context-specific state of
the downstream actuation machinery and its interaction with
targets in the cellular environment. Nevertheless these depend
fundamentally on the optical switch state, which is easily mea-
sured. Three alternative but less flexible methods were described
earlier to monitor generation of the activated state of LOV2 in
real-time. First, the weak fluorescence of resting-state LOV2
itself was directly measured in a bacterial screen37. The low
e
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Fig. 7 Minimal illumination conditions sufficient to inhibit the JNK pathway inhibition with mTq2-optoJNKi and demonstrate fluorescent tag-
dependent sensitivity of actuation. a To evaluate activation of the JNK pathway in real-time, multipoint epi-fluorescence microscopy of neurons
expressing JNK reporter was carried out during trans-illumination of selected wells by blue LEDs gated by microscope imaging acquisition. b Based on
parameters from Table 1, and a 1 s 0.06mW/cm2 flash of blue light every 7.5 s, the % of construct in adduct state stabilises after about 1 min as shown.
The mTq2 construct reaches approximately fivefold greater proportion in adduct state compared with the Ypet construct, whereas the mScarlet construct
exhibits minimal adduct state under these conditions. c–f Changes in cytoplasm:nuclear ratios of the JNK pathway reporter JNKktr (increased translocation
from the nucleus indicates activation of JNK) are shown in response to treatment with JNK-activator anisomycin. Cultured cortical neurons were infected
with AAVs encoding synapsin-promoter driven JNKktr fused to miRFP670 and optoJNKi fused to either mTq2, Ypet or mScarlet as shown. The light-on
samples (turquoise datapoints) were exposed to light as shown in a. The mTq2-optoJNKi expressing neurons exhibited significant light-dependent
inhibition, the Ypet-optoJNKi had a barely detectable and not significant effect in response to light whereas the mScarlet-optoJNKi expressing cells did not
respond to light. This is consistent with the predictions shown in b. Means ± SEM (n= 4 wells) are shown. ***P < 0.001, ns denotes non-significance, by
two-way ANOVA. Source data are provided as a Source Data file.
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fluorescence quantum yield (0.13 at room temperature) quenched
by elevated temperature38,39, low extinction coefficient and broad
spectra overlapping with multiple channels (Supplementary
Fig. 1) make LOV2 fluorescence inadequate for single-cell ima-
ging in practice. LOV2 is theoretically ~50-fold dimmer than
Ypet, making it sensitive to bleed-through errors in multichannel
experiments. Second, the conformational change in AsLOV2Jα
and optogenetic CaMKII inhibitor paAIP2 modified by fusion to
GFP and dark RET-acceptor ShadowY at N and C-termini gen-
erate detectable FLIM change7,40. However, this approach may
not be generally applicable; C-terminal fusion may inactivate
inhibitors requiring free C-termini (e.g. PDZ domain ligands41)
or when docking of the C-terminal residue of the inhibitor with a
LOV2 pocket is important for photo-regulation6. Moreover,
functionality of the modified construct used to demonstrate
photoactivation was unclear as it was not used for inhibition7.
Third, Murakoshi et al. (ref. 7) co-expressed Cherry-paAIP2 with
a GFP-fused version of the inhibitor target, CaMKII in this case,
to achieve a FLIM readout. This may not be routinely applicable
as (i) successful two-component RET is dependent on distance
and angle parameters not easily controlled, (ii) target over-
expression is usually undesirable in inhibitor experiments, and
(iii) the targets of optogenetic inhibitors are usually endogenous
signalling components that are not fluorescent. Moreover, our
results suggest that both EGFP and ShadowY-fused constructs
might, like Ypet fusions, exhibit RET and reduced sensitivity. Our
more generically applicable and simpler dequenching method,
requiring only a conventional microscope, could be a routine
alternative to these more technically challenging approaches.
A third consequence of RET with LOV2-bound FMN is the
in situ determination of relaxation time. Relaxation is typically
assumed a fixed LOV2 domain property albeit altered by muta-
tion3. Relaxation is faster at 37 °C in cell-free spectroscopic stu-
dies6,16, but actuators' relaxation measured in situ appeared even
faster. Jα modification has significant effects8, whereas the
photoregulated peptide has a modest impact6. Here we demon-
strated that the fluorescent tag usually has minimal impact but
the linker between tag and LOV2 has a strong effect. We conclude
that both temperature and the actuator sequence, both within the
LOV2-Jα and the N and C-terminal flanking sequences, each
contribute to define the relaxation time. It is important to
quantify relaxation rates of optogenetic actuators used, but these
are easily determined by LOV2FRET, either in situ or in cell
lysates. The former may have greater accuracy and experimental
relevance. However, the cases we compared showed no evidence
for an impact of the intracellular environment per se on
relaxation time.
In situ activation and relaxation parameters predict illumina-
tion requirements for actuation. The availability of in situ JNK
reporters allowed us to demonstrate this in practice with an
optoJNKi panel fused to different fluorophores (Fig. 7). However,
the straightforward calculation algorithm used (Supplementary
file) guides design of effective illumination sequences even when
in situ reporters are unavailable and on-line validation not
feasible.
Fast relaxation complicates multi-point objective-based ima-
ging and increases blue-light dosage. The AsLov2-V416I mutant
slows relaxation approximately tenfold3,23 and has occasionally
been implemented in optogenetic actuators24,25. Used in
optoJNKi, the in situ relaxation rate is still sufficient for investi-
gating the slow kinetics of the JNK pathway, while providing
tenfold reduced light exposure and increased experimental
throughput without loss of temporal precision. This allowed us to
show that transient suppression of a pathway offers repeatable
and relatively non-invasive in situ quantification of pathway
dynamics, during both inhibition and re-activation not achievable
by pharmacological approaches.
In summary, RET can sensitise an optogenetic switch >twofold
(sevenfold when replacing a red or yellow protein). RET also reports
real-time in situ activation state, revealing activation sensitivity and
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Fig. 8 RET allows mutational relaxation time optimisation to be monitored in situ. a Raw (vector-corrected) fluorescence quench-recovery cycles
captured from intact living HEK293 cells using the protocol used in Figs. 2–6 for quantitation of LOV2 switching and relaxation of optoNES constructs with
wild-type LOV2 or photocycle mutants V416I, I427V and F434L. These are tagged with Ypet because the LOV2 FRET responses are larger and clearer. The
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fits of vector-normalised quench-recovery data from a are shown. Curve fitting is performed as described in the methods and provides activation time
constants and dark dequench values plotted in c. c Relaxation time constants are estimated by exponential fits of the % of dequench values from b, and
best-fit values (±S.E., n= 3 wells) plotted against dark time preceding the dequench for each construct. The red crosses represent the initial dequench
value of the first measurement (taken as representing the dark state because the cells had not previously been exposed to light). Averaged parameters
based on the experiments in parts a–c are listed in Table 1B. Relaxation time constants for the fast photocycle mutants I427V and F424L are 10–20 times
shorter than the wild-type and V416I is about 10× longer. Relaxation is a consistent 10–15-fold faster than has been reported under cell-free conditions3,23.
The extents of activation of the fast relaxing mutants are low, because of the considerable concurrent relaxation taking place during the activation
conditions used. For the same reason apparent activation sensitivity and maximum dequench change inversely with relaxation rate. This is expected
because a slower relaxation allows a more complete activation during the illumination phases while faster relaxation counteracts apparent activation and
reduces the possible level of dequench at limiting photon flux. Source data are provided as a Source Data file.
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relaxation rates. These parameters guide selection of optical con-
ditions and implementation of mutants, reducing photon dose up
to tenfold while increasing experimental throughput tenfold.
Finally, this improved experimental throughput allows quantifica-
tion of changes in bidirectional pathway kinetics in intact living cells
over time.
Methods
Reagents and plasmids. Anisomycin was purchased from Sigma-Aldrich, and
Vincristine and Paclitaxel from Adooq. Dulbecco’s Modified Eagle Medium, Foetal
Bovine Serum, NeurobasalTM-A medium and B-27TM supplement were from
ThermoFisher Scientific. Other reagents were obtained from Worthington, Sigma,
Applichem, Apollo Scientific, NEB, ThermoFisher Scientific, Takara and VWR.
PCR templates for mScarlet, miRFP670 and Dronpa were generous gifts of
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Guillaume Jacquemet42 and Stefan Jakobs43. VinculinTS, a gift from Martin
Schwartz (Addgene plasmid # 26019; http://n2t.net/addgene:26019; RRID:
Addgene_26019; ref. 44) was used as a template for mTFP1. mTurquoise2 was
generated by PCR-based mutation from a SECFP template in a plasmid also
containing the Ypet template (generous gift of Michiyuki Matsuda). The JNKktr
insert was obtained by PCR from pENTR-JNKKTRmRuby2, a gift from Markus
Covert (Addgene plasmid # 59148; http://n2t.net/addgene:59148; RRID:
Addgene_59148; ref. 22). The AAV plasmid backbone was derived from pAAV-
hSyn-3xFLAG-WPRE (RRID:Addgene_127862), generated previously45. The
plasmids used in/built for this study are listed in Supplementary Table 3. The
optoJNKi (GenBank AQY77481.1, RRID:Addgene_89744), optop38i3
(AQY77484.1, RRID:Addgene_89749) and optop38i5 inserts were developed and
characterised previously6. The optogenetic optoNES cassette, consisting of LOV2
fused to NES219 was derived by PCR procedures from optoJNKi6 as a template and
linked to different fluorescent proteins as indicated in Fig. 1b and preceded by the
NLS motif sequence described in Niopek et al. (ref. 9). For cloning convenience the
linker used differs from the originally described LEXY construct, as the purpose of
this study was to evaluate the impact of RET on LOV2 switches in general, not
specifically to manipulate the original LEXY. OptoNES spacer constructs that are
used to increase the interdipole distance and reduce RET, replaced the N-terminal
NLS on the fluorescent protein tag with a 3 copy NLS sequence between the
fluorescent tag and the LOV2 domain, as shown (Supplementary Fig. 8). This was
achieved by ligating the LOV2-NES21 cassette into the corresponding 3xNLS
vectors. LOV2 constructs starting at residue 408 were obtained by PCR in a similar
way. Point mutants were generated by overlapping PCR. The remaining mod-
ifications were achieved by restriction and ligation to generate the corresponding
constructs. All constructs presented here for the first time (Supplementary Table 3)
are available through addgene.org.
Cell culture. Hippocampal and cortical neuron cultures were prepared from P0
rats of either sex (mixed)46. Briefly, rat hippocampi and cortices were dissected
separately in dissociation medium (81.8 mM Na2SO4, 30 mM K2SO4, 15.8 mM
MgCl2, 0.252 mM CaCl2, 1.5 mM Hepes, 20 mM Glucose, 1 mM Kynurenic acid,
pH 7.4) and digested with 50U papain, followed by 50U DNaseI treatment. Tissue
were triturated with 5 ml, 1 ml, 200 µl pipette tips (about ten times each)
sequentially until the cells were dissociated and homogenous. All isolation of cells
and tissues from animals was performed in accordance with corresponding local,
national, and European Union regulations, under approval number KEK/2015/
2508 issued and renewed by the University of Turku Central Animal Laboratory.
The cells were cultured in growth medium (NeurobasalTM-A medium supple-
mented with 2% B-27, 1 mM glutamine and 50 Uml−1 penicillin, 50 µg ml−1
streptomycin) and plated in 384 well plates in the concentration of 150,000 and
250,000 cells cm−2 for hippocampal and cortical cultures, respectively.
HEK293 cells were cultured in high glucose Dulbecco’s modified eagle media
supplemented with 10% (v/v) heat-inactivated foetal bovine serum, 2 mM
glutamine, 50 Uml−1 penicillin, 50 µg ml−1 streptomycin. Cells were maintained
in humidified 5% CO2 atmosphere at 37 °C. The cell line was from ATCC.
Generation of adeno-associated viruses (AAVs). HEK293 cells were plated in
six-well plates and transfected at 50% confluency with the AAV helper plasmid,
AAV-DJ replicase/capsid and AAV plasmid (Supplementary Table 3) at a ratio of
1:1:1 using the calcium phosphate co-precipitation method (see Transfection and
AAV addition, below). 72 h post-transfection, supernatant of the HEK293 cells
were collected and centrifuged at 500 × g, 10 min to remove cell debris. Cleared
supernatant were aliquoted, snap-frozen in liquid nitrogen and stored at −70 °C.
Transfection and AAV addition. For experiments in HEK293 cells, cells were
transfected with corresponding plasmids using the calcium phosphate co-
precipitation method, a procedure for which has been included in the step-by-step
protocol for RET-enhanced measurement of relaxation time constants of LOV2-
based actuators47. Briefly, for one 35 mm dish of cells, a total 2.5 µg DNA was
mixed with H2O and 6.25 µl 2.5 M CaCl2 at a total volume of 62.5 µl. DNA and
CaCl2 were added to the same volume of 2XHebs buffer (274 mM NaCl, 10 mM
KCl, 1.4 mM Na2HPO4, 15 mM D-glucose, 42 mM Hepes, pH 7.10) while swirling.
After 30 min incubation under ambient conditions, the suspension of precipitate
was distributed evenly over the cultures dropwise. For experiments in neurons,
corresponding AAV supernatants were added in the culture and experiments were
carried out 7 days after AAV addition.
Spectral comparisons. All FP spectra were obtained from FPbase48, except for
Dronpa off-state absorption spectra that were taken from ref. 11. LOV2-bound
FMN spectra were obtained from ref. 38.
Image acquisition. For imaging, neurons were plated in 384 well cell carrier plates
(Perkin Elmer cat 6057302) and HEK293 cells were plated on 96-well microclear
plates (Greiner cat 655090). All image data were acquired with a BD pathway 855
High-Content Analyzer (Beckton Dickinson) running Attovision V1.6, equipped
with high power LED sources at 405, 445 and 623 nm, as well a white light LED
source (SOLIS-405C, 445C, 623C and 3C, respectively, Thorlabs). mTurquoise2,
Ypet, mScarlet and miRFP670 were excited through 438/24 nm, 500/20 nm, 555/28
nm, and 635/20 nm excitation filters, and dichroics at 458, 515, 595 nm, and a
multiband dichroic for the miRFP670 channel (Chroma #84000). Images were
acquired through emission filters 483/32 nm, 542/27 nm; 645/75 nm and 745/75
nm. Filters were from Semrock and Chroma. The LEDs were electronically shut-
tered through an optocoupler/double-inverter TTL circuit for precise exposure
times and synchronisation with camera acquisition. The rest of the imaging system
was controlled by Attovision software with macros according to the experimental
design as described below. All quantifications were carried out on images acquired
with a ×10 N.A.0.4 air objective (Olympus). Example images in Fig. 1a and Sup-
plementary Fig. 5 were acquired with a ×40 N.A. 0.95 air objective (Olympus).
Binning of 2 was used in all cases, with a resulting pixel size of 1.2 and 0.30 µm with
the low and high magnification objectives respectively.
Nuclear translocation imaging. In Fig. 1, multiple miRFP670 images were cap-
tured to localise nuclear regions, followed by ten images each of mTurquoise2, Ypet
and mScarlet at a rate of one every 10 s. The next well was then imaged and any
one well was not visited again for at least 10 min to allow recovery of nuclear
translocation. Exposures for miRFP670 (1 s), Ypet (0.5 s) and mScarlet (1 s) were
kept constant in all cases and 438 nm exposure for mTurquoise2 and LOV2
activation was varied over the range indicated in the figures (10, 30, 100 and 300
ms, corresponding to 14–420 µmol photons.m−2) to determine the sensitivity of
the response. To ensure consistent exposure conditions in all cases, all wells were
exposed to the same series of excitations regardless of whether the well expressed
only one fluorophore or all three. Each well was revisited for each exposure setting
(10–300 ms) and this was repeated multiple times. The data shown for mTq2, Ypet
and mScarlet fusions of optoNES were obtained from an average of four visits at
each setting using hippocampal neurons at 8 days in vitro (n= 6 replicates).
In the case of Dronpa-optoNES, the experimental comparison in Fig. 1 (and
Supplementary Fig. 9) was between Dronpa-off and Dronpa-on state at distinct
illumination intensities. We established the sensitivity of Dronpa to photoswitching
in our system in pilot experiments. Dronpa is known to be switched to fluorescent
state with exposure to 405 nm light, and to non-fluorescent 400 nm-absorbing state
Fig. 9 Optimisation of relaxation in optoJNKi-sr increases sensitivity and experimental throughput tenfold, facilitating investigation of bidirectional
pathway dynamics in intact living cells. a Neurons expressing mTq2-optoJNKi and miRFP670-JNKktr were exposed to chemotherapeutics (Vincristine
and Paclitaxel, 100 nM each). The JNK pathway was measured during alternating periods of blue light flashes and darkness; b After 6 h, JNK reporter
activity increases steadily. Using the original optoJNKi, blue light (420 µmol m−2 438 nm every 2min, 8.3 mHz, vertical blue lines) has no affect. Predicted
adduct levels decay rapidly after each flash (inset); c 11 h after addition of chemotherapeutics, the reporter response has stabilised, and tenfold increased
flash rate (every 12 s, 83mHz) achieves detectable slow reduction of JNK reporter response, consistent with adduct prediction (inset). The reporter
response gradually recovers in darkness; d Experiments in c are repeated using optoJNKi-sr, harbouring AsLOV2-V416I in as in Fig. 8, slowing relaxation
tenfold (Supplementary Fig. 14). The lower flash rate (8.3 mHz) is now sufficient to maintain substantial adduct state (inset) and inhibit the pathway, as
judged by the reporter readout, while reducing tenfold both photon dose and time spent on an imaging field. The latter permits the imaging of multiple
samples in parallel (12 here compared with only 1 in b, c. e Samples, 11 h after chemotherapeutic addition, were imaged as in d with an extended actuation
period (60min every second hour) repeated five times. Inhibition and recovery reaches equilibrium in lit and dark phases. f The averaged JNK pathway
reporter responses to light in d, e were fitted to exponentials with best-fit time constants shown (tau) as estimates of the reduction and recovery rates of
reporter activity. Comparison of time-constants by F-test indicates significant two- to threefold differences between rates of inhibition and reactivation 20’
later (F(1,15)= 13.46) and of reactivation after 20’ vs. after 60’ inhibition (F(15, 55)= 9.611), suggesting different reactivation mechanisms depending on
the duration of inhibition. The small difference between inhibition and reactivation rate at 60’ is also seen (F(1,55)= 39.61). ***P < 0.0001, **P= 0.0023,
n.s. not significant. Source data are provided as a Source Data file. Means ± SEM (n= 4 wells) are shown in b–e.
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(Supplementary Fig. 9, <10% maximal fluorescence11,43) with 488 nm light. The
spontaneous relaxation is from dark-state back fluorescent state with a reported
half-time of 840 min43, therefore there will be no significant relaxation during our
experiments. We found 438 nm light was able to cause Dronpa on-switching, but
470 nm, which is similarly absorbed by LOV2 (Supplementary Fig. 1), could not.
Therefore 470 nm was selected for LOV2 switching in place of 438 nm so as to
avoid simultaneously affecting Dronpa state. With our illumination system, we
were able to switch Dronpa off most effectively with 500 nm light (~80% drop in
fluorescence with 30 s exposure) so this was selected for the Dronpa off-switching
phase. At 405 nm, we achieved ~20% reactivation in 0.1 s. Therefore in the
experiments we used 300 s at 500 nm, equivalent to 0.231 mol m−2 to switch
Dronpa off (~10% of initial fluorescence, Supplementary Fig. 9E), and 0.5 s at 405
nm (2.3 mmol m−2) to switch Dronpa on just prior to a 500 nm image (0.1 s,
equivalent to 77 µmol m−2) to visualise nuclear:cytoplasmic distribution. To ensure
similar imaging conditions are used for quantifying nuclear:cytoplasmic ratio when
Dronpa was in off or on state, only this 500 nm image was used to determine the
ratio. Therefore, unlike Fig. 1, where the ratio was measured ten times during the
LOV2 activation, in the Dronpa case, the ratio was only measured once at the end
of each LOV2 activation series. After the LOV2 activation, Dronpa-on switching
and single 500 nm image acquisition, cells were allowed to recover for 5 min. Prior
to the second LOV2 activation of the cycle, with Dronpa in on-state in this case, a
500 nm image was acquired to determine the resting state ratio. This was used as a
baseline ratio to quantify the response caused by each LOV2 activation train in the
cycle. In all experiments three such cycles, as shown in Supplementary Fig. 9, were
carried out. Average ratio changes after LOV2 activation were determined by
subtracting the averaged baseline ratio. These single average LOV2 response values
for Dronpa-on and Dronpa-off were used as individual replicate values, at each of
four LOV2 activation intensities used, and data from six-wells were used to
determine mean ± S.E.M. values. The data (six replicates for each of four photon
doses) were fitted to a single site model with a common maximum response
parameter. Graphpad Prism was used (see curve fitting, below) to calculate the
best-fit ED50, corresponding standard error and to apply an F-test to determine the
statistical significance of the difference between the EC50s. The filters used for this
protocol were 405/20 excitation to switch Dronpa on, 470/40 excitation to activate
LOV2 without affecting Dronpa, 500/20 excitation to switch Dronpa off, and 500/
20 excitation, 515LP dichroic and 515LP emission.
Imaging-based quantification of LOV2FRET. In Figs. 2–6 and 8, HEK293 cells
were transiently transfected with AAV plasmids. Expression from the plasmids
used was driven by human synapsin I promoter in all cases. Although this is a
neuron-specific promoter when DNA is delivered at low copy number as an AAV
particle, we find that the promoter generates low level expression in HEK293 cells
under transient transfection conditions while avoiding overexpression issues. The
purpose of the RET imaging was to monitor changes in emission of a fluorophore
—mTurquoise2, Ypet or mScarlet—fused to LOV2 during switching from LOV2-
445 to LOV2-390 during repeated flashes of 438 nm light (at about four times a
second) and relaxation back to LOV2-445 during darkness for the time period
specified in the figures. As even well-optimised fluorescent proteins intrinsically
exhibit a level of partial rapid photobleaching49,50, it was important in these
experiments to normalise this data to the properties of LOV2-free fluorescent
protein control plasmids under identical conditions. A small initial quench was
observed with unfused mTurquoise2 protein used as a control (Supplementary
Fig. 10), therefore all dequenching data presented in this report are normalised to
identical experiments using the corresponding unfused fluorescent protein
expressing cells as a control.
JNK pathway imaging, LOV2 activation and cell stimulation. For experiments
shown in Fig. 7, cerebrocortical cultures were infected with AAVs encoding the
fluorescently tagged optoJNKi construct as specified, together with a nuclear seg-
mentation marker fused to a different fluorescent tag, and the JNKktr reporter
previously described22 in this case fused to miRFP670 and inserted into an AAV
plasmid. For mTurquoise2 and Ypet-optoJNKi, Cherry-3xNLS was used as a
segmentation marker. For mScarlet-optoJNKi, Ypet-x3NLS was used. This allows
capture of nuclear images for segmentation without activating the LOV2 domain.
All data acquired was from neurons because the constructs, listed in Supplemen-
tary Table 3, were expressed from the neuron-specific human Synapsin1 promoter.
A final 2 µg ml−1 anisomycin was added to the neuronal culture immediately
before imaging. The wells defined as light-off were sealed with aluminium sealing
film (Costar) and the wells with light on were sealed with transparent sealing film
(Sarstedt). An array of addressable LEDs (SMD5050/WS2812B, Adafruit), one LED
above each group of 4 wells of a 384 well plate, was placed above the cell plate
(Fig. 7a) to provide pulsed blue illumination centred around 465 nm. The LED
array was controlled by a microcontroller synchronised via double-inverter circuit
to the TTL driven camera/microscope excitation path to limit simultaneous
exposure from above the plate during image acquisition and provide illumination
as defined in Fig. 7b. Images were acquired for yellow (Ypet) or red (mCherry/
mScarlet) and infra-red (miRFP670) channels as defined in the Imaging section
above. Each well of a group was visited in turn, amounting to one visit every ~400 s.
During each visit one pair of infra-red (JNKktr reporter) and red (nuclear marker)
images was captured from a single field per well. For wells expressing mScarlet-
optoJNKi and Ypet-3xNLS, yellow images were taken in place of red images. The
yellow or red images were used for segmentation and the nuclear:cytoplasmic ratio
of miRFP670 was taken as an indicator of activation of the JNK pathway22.
Calculation of nuclear translocation. All acquired image time-stacks were
background-subtracted (rolling ball 50 pixels) and aligned in groups of 10. For each
series of 10 time points at 10 s intervals, a maximum projection of the preceding
miRFP670-3xNLS image time-series (15 images) was used to segment nuclei. These
initial nuclear ROIs were eroded for the final nuclear ROIs for calculation, and
expanded as a band to define a cytoplasmic ROI. For simplicity, and considering
that it is neither practical nor necessary to accurately capture the entire cytoplasm
of a neuronal cell under our conditions, cytoplasmic ROIs were not further pro-
cessed and therefore contained some background area. This means the cytoplasmic
ROIs were consistent under-estimates. Thus a visually even nucleocytoplasmic
distribution (e.g. Fig. 1a, first frame) generated a nuclear:cytoplasmic ratio >1 (e.g.
average 2.37 for mTq2-optoNES, Supplementary Table 1). This systematic nuclear
bias as described was applied blindly to all samples and should not affect the
relative changes. Most importantly it will not affect the rank photon-sensitivity of
the different constructs which is orthogonal to the actual ratio values. Similarly,
although spacer constructs had a more effective NLS sequence (Supplementary
Fig. 8 and Supplementary movies 4–6), evidenced by over twofold higher baseline
nuclear:cytoplasmic ratios (Supplementary Table 1), this should not affect the
photon-sensitivity of the constructs. Mean intensities in nuclear and cytoplasmic
ROIs were used for thresholding (removal of very dim and very bright cells) and
remaining ROIs were used to determine nuclear:cytoplasmic ratios at each time
point. At each time point ratios from all cells in a field were averaged to generate a
single ratio per time point for each 438 nm exposure and each well revisit. Indi-
vidual time point values for each well revisit were averaged to improve signal to
noise ratio. This generated data from each microscope field as shown in Fig. 1c.
Only one field was captured from each replicate. Linear regression yielded a gra-
dient and offset value from data from each well for each 438 nm photon dose, the
gradient representing the rate of change of nuclear:cytoplasmic ratio per flash of
light at the given dose. Means ± SEM of these values were determined from six
replicates for each construct shown in Fig. 1 and these were plotted against photon
dose as shown in Fig. 1e, f. Each gradient-dose curve was fitted to a single-site
model
Response ¼ Max ´ PhotonDose= ED50 þ PhotonDoseð Þ; ð1Þ
using GraphPad Prism software to derive best-fit photon sensitivity and max
response values and their standard errors, as shown in Supplementary Table 1. All
scripts and data are available.
Calculation of fluorescent protein dequenching and quenching in situ. Quench
and dequench experiments were carried out on HEK293 cells transfected with a
single fluorescent construct only, as indicated. Images were acquired by repeated
imaging and, for relaxation time calculations, defined periods without imaging as
indicated in the figures. The pattern shown was repeated to allow data averaging
and reduction of signal to noise. Image time-stacks were background-subtracted
(rolling ball 200 pixels). ROIs were generated by segmentation of maximum pro-
jections of the entire image timecourse sets in each case. Intensities from all ROIs
segmented in each field were averaged. Only one field was captured per well, but
repeated data captured from each field was averaged, for each time point. This
provided one quench/dequench curve per replicate for each condition and averages
of replicates are shown. SEMs are not shown in all the main figures for clarity but
are available in the source data for each figure.
Acquired dequenching curves in response to 438 nm illumination of mTq2-
LOV2 constructs (Figs. 2–5, 8) were fitted to exponentials and the corresponding
quench curves (for Ypet and mScarlet fusions) were fitted similarly (Fig. 6 and
Supplementary Fig. 13), providing time constants and max. apparent dequench/
quench (at the given intensity; lower intensity results in reduced max. apparent
dequench/quench because of concurrent relaxation—see Fig. 2e). Repeated
dequench/quench-relaxation curves (Figs. 3–6, 8) were fitted to a common time
constant but freely fitted max. apparent dequench/quench. In the relaxation
experiments, the apparent dequench or quench was plotted against the preceding
dark time and this curve fitted to an exponential to derive relaxation time constants
and a better estimate of apparent dequench/quench (given the concurrent
relaxation). The derived constants are shown together in Table 1.
Calculation of JNK pathway activity. Activation of the JNK pathway reporter
JNKktr22 was quantified as the ratio of reporter signal detected in nuclear and
cytoplasmic compartments. These were obtained with ImageJ scripts similar to that
used for the analysis described in the section Calculation of Nuclear translocation.
Multi-channel image time-stacks were background-subtracted (50 pixel rolling ball
subtraction) and aligned. The locations of cell nuclei were determined by seg-
mentation of maximum projection images of NLS-fused fluorescent proteins
imaged, as described in the section JNK pathway Imaging. Nuclear and cytoplasmic
ROIs were defined as described in the section Calculation of Nuclear translocation.
Intensity ratios between cytoplasmic-nuclear ROI pairs were calculated, after
thresholding each ROI for minimal and maximal intensities to remove very dim
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cells and near-saturating cells. Raw ratio values were averaged from all cells in a
field, and normalised to the first two time points of each well. Normalised field-
average response curves were used to generate mean ± SEM time course curves
shown in Figs. 7 and 9.
Light calibration. Intensities at the sample plane were determined with a power
metre with microscope-stage attachment (Ex-Cite XR2100 with X-Cite XP750,
LDGI), set for the relevant central wavelength.
Measurement of dequench recovery in cell lysates. A step-by-step protocol for
RET-enhanced measurement of the relaxation time constants of LOV2-based
actuators has been deposited at protocol exchange47. HEK293 cells were transiently
transfected with CMV-driven optoNES, mTq2dC7-408LOV2-NES21, mTq2dC10-
408LOV2-NES21, mTq2dC11-408LOV2-NES21 constructs using calcium phos-
phate precipitation. Cells were lysed 48 h post-transfection with low stringency
buffer (LSB51) supplemented with protease inhibitors and detergent 0.5% Igepal.
Lysates were cleared by centrifugation at 20,000 × g, 4 °C for 10 min. In total, 20 µl
of cell lysate was transferred to a half-area 96 well µClear plate (Greiner cat 675090)
and 5 µl of mineral oil (Sigma-Aldrich) was added to prevent evaporation. Before
each measurement, the plate was equilibrated to either 25 or 37 °C in a plate reader
(POLARstar OPTIMA, BMG) for 5–10 min. The stability of the dark state was
determined by measurement after temperature equilibration. The adduct state was
generated by 30 s exposure to blue LEDs (peak ~465 nm) at 2 mW cm−2 using the
96 well trans-illuminator device described above under the section JNK pathway
imaging, LOV2 activation and cell stimulation6. The recovery to dark state was
quantified as a recovery from dequench by transferring the plate to the reader and
starting the measurement protocol immediately. This protocol consisted of mea-
surement cycles set to flying mode (3 xenon flashes per well). The excitation filter
(430/10 nm) and the emission filter (475/10 nm) were used. Only 8 wells were used
per measurement to minimise the cycle time (3 s per cycle). A total 20 cycles were
measured, corresponding to 20 flashes over 1 min in each of three positions per
well. In a pilot experiment, even 50 Hz xenon lamp flashes at a single point in a
single well caused relatively slow dequenching, indicating the 0.3 Hz flashes per
point required for sample measurement itself caused insignificant LOV2 re-
activation. A total of eight replicate samples were measured for each construct.
Background signal from 20 µl untransfected 293 cell lysate was subtracted from
the raw signal of each construct. All cycles were normalised to the first
measurement of individual construct, and the data was fitted to an exponential
decay with Graphpad Prism.
Statistical analysis. In many cases individual samples were measured repeatedly,
in which case the measurements were averaged and considered a single biological
replicate. In all cases, n refers to distinct samples not separate measurements from
the same sample. One-sided tests were not used in the statistical analyses except
where indicated.
Curve-fitting approach and statistical analysis. Curve-fitting was carried out
preliminarily in excel and subsequently using Graphpad Prism to obtain standard
error estimates, in which case symmetry was assumed. Although this was necessary
for the statistical analysis of curve-fit derived estimates in Fig. 4f, statistical sig-
nificance evaluated by F-test (Fig. 1g, h, 9f) did not require this assumption.
Formulae used were as follows:
Curve fitting to the single-site model. A single-site model as follows was used to
determine the photon sensitivity as an ED50
y ¼ a= 1þ b=xð Þ; ð2Þ
where y is the measured response, x is the photon dose in µmol m−2 provided, a is
the maximum response, and b is the ED50 or 50% effective photon dose derived.
Statistical evaluation of differences between sample groups was carried out on
selected parameters (photon sensitivity) by F-test (Fig. 1g, h).
Curve fitting of activation cycles, variable dose (first order reversible kinet-
ics). For activation experiments, all datapoints were fitted to the formula
F ¼ constant: 1 Dlimit þ Dmax dose½ :ekapp:t
 
; ð3Þ
where Dmax[dose]=Dlimit/(1+ kr/kf), kapp, the apparent forward rate constant= kf
+ kr, kf, the forward rate constant= dose/sensitivity, and kr, the reverse rate con-
stant= 1/r, the relaxation time constant.
In Prism this was expressed as
Y ¼ Plateaumax ´ ð1 Dlim ´ ð1 ð1=ð1þ ðsens=ðdose ´ rÞÞÞÞ ´ ðexpððð1=rÞ
þ ðdose=sensÞÞ ´ xÞÞÞÞ;
ð4Þ
and ED50 was calculated as sens/r
Significant differences in best-fit parameters were determined in Table 1 with
PRISM based on the manufacturer’s instructions (https://www.graphpad.com/
guides/prism/7/curve-fitting/index.htm?reg_comparing_fits_with_anova.htm)
using the standard errors of the best-fit parameters and degrees of freedom for each
value by one-way ANOVA followed by Bonferroni’s multiple comparisons test.
Differences between parameters for optoNES and either spacer- optoNES or
optoJNKi are shown (****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; ns P >
0.05); df= 593, or 394 for Ypet-spacer-optoNES and mScarlet-optoJNKi (because
signals using the lowest illumination intensity did not pass threshold, and second
lowest passed threshold only in two of three replicates). In the case of the curve-
fitting of the data in Fig. 2c, d the first of the 50 datapoints, was discarded due to an
evident systematic artefact affecting most replicates, probably related to the
imperfect correction to the control in this case (Supplementary Fig. 10A). No other
data points were discarded in this or any other experiment.
Estimation of dark relaxation rate from activation-relaxation cycling (Table 1
first columns). The entire dataset was fit to the equation:
F x½  ¼ Flimit  A t½  ´ ex=Tau; ð5Þ
where x= the reading number (i.e. flash number), F[x]= the fluorescence mea-
sured (arbitrary units) at reading x, Flimit= the fitted fluorescence limit as exposure
(# flashes)→∞, A[t]= the fitted recovery from (de)quenching after the defined
dark period t, and Tau= the shared activation rate constant in units of flashes,
=kapp/photon dose per flash
In Prism, each of the 12 cycles occupies a separate data column with unique A
[t] but shared Tau (see source data). In Excel the data can be fitted as a single
column with row-specific A[t] values but this does not directly provide standard
errors of the fitted constants. In Figs. 3e, 6c, 7, the apparent activation rate or
forward rate constant is shown as kapp in µmol m−2 at the photon dose per
flash used.
The At values obtained above for each dark time were plotted against dark time
t and fitted to the exponential
A t½  ¼ A0 ´ 1 et=r
 
; ð6Þ
where, t= the dark time, A[t]= the best-fit values of the recovery from
dequenching or quenching after the dark time t, from the curve fit above, A0= the
fitted maximal increase in fluorescence as dark time→∞, and r= the relaxation
time constant, shared across cycles with the same construct.
This curve is shown in Figs. 3d, 4d, 5c, 6d, g and 8c, where the dequench or
quench maxima at the photon doses uses were calculated from the maximal change
in fluorescence as a fraction of the maximal fluorescence. Thus max. dequench
max. at the photon dose per flash specified in the tables=A0/(1+A0) as a %.
Quantification of dequench limit, ED50 and sensitivity. The above fit was carried
out to help visualise the quench and dequench recovery under the conditions used.
To acquire more fundamental properties the equation below was fitted to all
datasets. One exception was the mTq2-optoNES v mTq2-spacer-optoNES dataset
(Fig. 3). In this case the response of the spacer construct was low and the fits to
individual datasets generated a poor fit. Therefore the averages (n= 5−6) were
used instead for fitting to the equation below, which produced a much better fit.
Dequench limit, sensitivity and ED50 was obtained by fitting all datapoints to
the following formula:
Y ¼ Offset ´ 1 Dlimit þ Dmax dose½  ´ 1 1 ekr:t
 
:ekapp:x=4
h i  
; ð7Þ
where Dmax[dose]=Dlimit/(1+ kr/kf); kapp= the apparent forward rate constant=
kf+ kr, kf= the forward rate constant= dose/sensitivity, 56/sensitivity in µmol m−2
in this case, kr= the reverse rate constant= 1/r, the relaxation time constant.
In Prism this equation was expressed as:
Y ¼Offset ´ ð1 Dlim ´ ð1 ðð1=ð1þ ðsens=ð56 ´ rÞÞÞÞ
´ ððexpðdarktime=rÞ  1Þ ´ expðx´ ðð1=rþ 56=sensÞ=4ÞÞÞÞÞÞ; ð8Þ
where the fluorophore acted as an acceptor and was quenched, the following
equation was used instead, providing values for quench limit, sensitivity and ED50
Y x½  ¼ Offset ´ 1 Qmax dose½  ´ 1 1 ekr:t=r
 
´ 1 1 ekapp:x=4
  h ih i
;
ð9Þ
where Qmax[dose]=Qlimit/(1+ kr/kf), kapp= the apparent forward rate constant=
kf+ kr, kf= the forward rate constant= dose/sensitivity, 560/sensitivity in µmol m
−2 in this case, and kr= the reverse rate constant= 1/r, the relaxation time
constant.
In Prism this equation was expressed as:
Y ¼ Offset ´ ð1 ððQlimit=ð1þ ðsens=ð560 ´ rÞÞÞÞ ´ ð1 ð1 expðdarktime=rÞÞ
´ expðx´ ðð1=rþ 560=sensÞ=4ÞÞÞÞÞ;
ð9Þ
In both cases, ED50 was calculated from sensitivity/4r.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18816-8
16 NATURE COMMUNICATIONS |         (2020) 11:5107 | https://doi.org/10.1038/s41467-020-18816-8 | www.nature.com/naturecommunications
Dark periods were 1–180 s as shown. The first dequench was set arbitrarily as
600 s because a minimum of 10 min was left between well revisits and this is far
above all time constants measured.
Analysis of JNKktr reductions and recoveries. Data from all replicates (n= 4)
and all reduction phases or recovery phases (4–5 repeats per replicate), during
blue-light illumination or blue-light darkness were averaged. The averaged curves
were fitted to exponentials. The impact of replacing the dark-phase recovery time
constant with an exponential decay, corresponding to the slow relaxation of the
optoJNKi-sr inhibitor, was considered. Thus in the parameter e-(kf+kr).t, the
uninhibited forward rate constant kf was replaced with (1-A.e−r.t).kf where A
represents the maximal fractional reduction of kf by the optogenetic inhibitor, and
r the rate constant at which optogenetic inhibitor relaxes, ~2 min in this case. This
had minimal effect (~10%) on fitted time constants, even on the fastest kinetics.
Therefore the slowed relaxation of optoJNKi-sr cannot explain the slower recovery
of JNKktr signal after 20’ inhibition compared with after 60’ inhibition (Fig. 9d, e).
This decaying time constant was not routinely included, to limit the number of
unknowns in the curve-fit formulae. To compare JNKktr reduction and increase in
the same curve fit for each experiment, spans were set as a shared variable, and the
fitted constants were compared by F-test, the results of which are cited in the figure
and in the results text.
Simulation of adduct state fraction. It is possible to simulate the expected pro-
portion of actuator in adduct fraction over time, on the basis of the optogenetic
actuator sensitivities and relaxation times, together with specific input of blue light
over time. Sensitivities used were based on measurements with 438 nm light, because
AsLOV2 absorbance at 438 nm (used in microscopy) and 465 nm (from the parallel
LED trans-illuminator device) are very similar. An excel sheet generating the simu-
lation with the desired time step resolution is provided as a Supplementary file.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. Figure data are in source data files. Raw
imaging data, together with associated metadata files, for Figs. 1–9 are available at https://
doi.org/10.5281/zenodo.388257252. Scripts used for controlling the image acquisition are
within this metadata. All data in this manuscript are available from the corresponding
author upon request. All plasmids used in this manuscript were new plasmids and
deposited in addgene under IDs 159941-159976. They are described in detail in
Supplementary Table 3. These plasmids were generated in part with the help of
previously generated plasmids (including addgene IDs 89744, 89749, 127862) and
plasmids provided by other labs (including addgene IDs 26019, 59148). The FBbase
database was also used for this work (https://www.fpbase.org/). Any other relevant data
are available from the authors upon reasonable request. Source data are provided with
this paper.
Code availability
Scripts for analysing the optoNES translocation and in situ photocycling, outputting the
source data, are in Supplementary files. The excel calculator for predicting adduct state
over time is in the Supplementary files.
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